Health News
FDA Approves Lenalidomide
On June 5, 2013, the US Food and Drug Administration approved lenalidomide capsules (REVLIMID, Celgene Corporation), for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.
These Cells Can Stem Blood Cancer
Being diagnosed with leukemia or lymphoma can be a major life change for patients. With new advances in medicine, they may have some respite.
New and Improved Leukemia Rx
Though more common in adults, acute myeloid leukemia (AML) is the second most common type of blood cancer in children. If untreated, the disease can be fatal in just a few months.
Non-Hodgkin Rx Trial Halted
A new medication that was thought to hold promise for non-Hodgkin lymphoma has been stopped. Pfizer announced it has halted its trial of the investigational compound inotuzumab ozogamicin.
FDA Grants Janssen Research & Development Breakthrough Therapy Designation for Daratumumab
Janssen Research & Development, LLC (Janssen) announced the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for daratumumab for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and IMiD.
Cancer Rx Prices Too High!
Today, people with chronic myeloid leukemia (CML) are leading pretty much normal lives. They can thank a variety of medications for being alive.
Winning the War against Childhood Cancer
Children shouldn’t experience cancer. The disease should be left to those who’ve spent a few more years on this earth.
Back to Hospital after Stem Cell Transplant
Stem cell transplants can – and do – save the lives of very sick kids. New research has discovered that the transplant is often just the start of hospital stays for these young patients.
Completely New Way to Treat Childhood Cancer
Scientists have entered a brave new world when it comes to treating childhood leukemia. New therapies now being tested may completely change the way one type of blood cancer is treated in children.
Pfizer’s BOSULIF Receives Conditional Marketing Authorization From The European Commission
Pfizer Inc. announced today that the European Commission (EC) has granted conditional marketing authorization for BOSULIF ® (bosutinib) in the European Union (EU) for the treatment of adult patients with chronic phase (CP), accelerated phase (AP) and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) (TKIs) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.